IE
BTAI icon

Israel Englander’s BioXcel Therapeutics BTAI Stock Holding History

Israel Englander’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.98M Buy
2,114,710
+177,950
+9% +$208K ﹤0.01% 3485
2026
Q1 		$2.6M Buy
1,936,760
+101,568
+6% +$167K ﹤0.01% 3614
2025
Q4 		$2.94M Buy
1,835,192
+807,139
+79% +$1.66M ﹤0.01% 3583
2025
Q3 		$2.63M Buy
+1,028,053
New +$3.24M ﹤0.01% 3793
2025
Q1 		– Sell
-6,561
Closed -$39.2K – 5887
2024
Q4 		$39.2K Sell
6,561
-1,487
-18% -$12.4K ﹤0.01% 5626
2024
Q3 		$78.6K Buy
8,048
+376
+5% +$5.05K ﹤0.01% 5622
2024
Q2 		$157K Buy
7,672
+4,852
+172% +$162K ﹤0.01% 5222
2024
Q1 		$127K Sell
2,820
-2,677
-49% -$128K ﹤0.01% 5518
2023
Q4 		$259K Sell
5,497
-3,714
-40% -$206K ﹤0.01% 5041
2023
Q3 		$373K Buy
+9,211
New +$931K ﹤0.01% 4822
2022
Q3 		– Sell
-11,784
Closed -$2.49M – 7076
2022
Q2 		$2.49M Buy
11,784
+10,572
+872% +$2.22M ﹤0.01% 3479
2022
Q1 		$405K Buy
1,212
+9
+0.7% +$2.61K ﹤0.01% 5284
2021
Q4 		$391K Buy
+1,203
New +$516K ﹤0.01% 5278
2021
Q2 		– Sell
-912
Closed -$630K – 6546
2021
Q1 		$630K Sell
912
-2,910
-76% -$2.34M ﹤0.01% 4629
2020
Q4 		$2.83M Sell
3,822
-1,373
-26% -$1.07M ﹤0.01% 2947
2020
Q3 		$3.6K Buy
5,195
+3,122
+151% +$2.34M ﹤0.01% 2111
2020
Q2 		$1.76M Buy
+2,073
New +$1.35M ﹤0.01% 2627
2019
Q2 		– Sell
-804
Closed -$127K – 4073
2019
Q1 		$127K Buy
+804
New +$99.1K ﹤0.01% 3815
2018
Q3 		– Sell
-2,862
Closed -$421K – 3908
2018
Q2 		$421K Buy
2,862
+931
+48% +$142K ﹤0.01% 3244
2018
Q1 		$316K Buy
+1,931
New +$322K ﹤0.01% 3193

Other funds holding BTAI

OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Israel Englander's BTAI Position: Q2 2026 in Review

Israel Englander increased its BioXcel Therapeutics (BTAI) stake by 9.2% in Q2 2026, buying an estimated $208K and bringing the position to 2,114,710 shares worth $2.98M. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Israel Englander first reported a position in BTAI in Q1 2018 and has held it in 20 quarters since. 46 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Israel Englander held 2,114,710 shares of BioXcel Therapeutics worth $2.98M as of Q2 2026.
  • Israel Englander bought 177,950 BioXcel Therapeutics shares in Q2 2026, an estimated $208K.
  • BioXcel Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3485 holding.
  • Israel Englander first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 20 quarters since.
  • 46 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.